Skip to content
naulon

No retraction, correction or concern found when last checked on Oct 17, 2026.

Free fatty acid binding pocket in the locked structure of SARS-CoV-2 spike protein

Christine Toelzer, Kapil Gupta, Sathish K. N. Yadav and 13 more

Science · 2020 · CC BY

doi:10.1101/2020.06.18.158584

Abstract

Locking down the SARS-CoV-2 spike Many efforts to develop therapies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are focused on the spike (S) protein trimer that binds to the host receptor. Structures of trimeric S protein show its receptor-binding domain in either an up or a down conformation. Toelzer et al. produced SARS-CoV-2 S in insect cells and determined the structure by cryo–electron microscopy. In their dataset, the closed form was predominant and was stabilized by binding linoleic acid, an essential fatty acid. A similar binding pocket appears to be present in previous highly pathogenic coronaviruses, and past studies suggested links between viral infection and fatty acid metabolism. The pocket could be exploited to develop inhibitors that trap S protein in the closed conformation. Science , this issue p. 725

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 17, 2026. Paragraph numbers are ours, so an answer can point at one.

Seven coronaviruses are known to infect humans. The four endemic human coronaviruses (HCoVs)—OC43, 229E, HKU1, and NL63—cause mild upper respiratory tract infections, whereas pandemic virus SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) and earlier SARS-CoV (severe acute respiratory syndrome coronavirus) and MERS-CoV (Middle East respiratory syndrome coronavirus) can cause severe pneumonia with acute respiratory distress syndrome, multi-organ failure, and death.

SARS-CoV-2 has acquired functions that promote its harsh disease phenotype. SARS-CoV-2 causes severe inflammation and damage to endothelial cells in the heart, kidneys, liver, and intestines, suggestive of a vascular infection rather than a purely respiratory disease. The attachment of SARS-CoV-2 to a host cell is initiated by the spike (S) protein trimer, which adorns the outer surface of the virus, binding to its cognate receptor angiotensin-converting enzyme 2 (ACE2) with higher affinity than the SARS-CoV S protein. A S1-S2 polybasic furin protease cleavage site distinguishes SARS-CoV-2 from SARS-CoV and other closely related bat coronaviruses and serves to stimulate entry into host cells and cell-cell fusion. Inside the host cell, HCoVs remodel the lipid metabolism to facilitate virus replication. Infection by SARS-CoV-2 triggers an unusually impaired and dysregulated immune response and a heightened inflammatory response, working in synergy with interferon production in the vicinity of infected cells to drive a feed-forward loop to up-regulate ACE2 and further escalate infection.

In the search for additional functions that contribute to the pathology of infection, we determined the structure of the SARS-CoV-2 S glycoprotein by cryo–electron microscopy (cryo-EM) (Fig. 1). We produced SARS-CoV-2 S as a secreted trimer in MultiBac baculovirus-infected Hi5 insect cells (fig. S1). Highly purified protein was used for cryo-EM data collection (fig. S2 and table S1). After three-dimensional (3D) classification and refinement without applying symmetry (C1), we obtained a 3.0-Å closed conformation from 136,405 particles and a 3.5-Å open conformation with one receptor binding domain (RBD) in the up position from 57,990 particles (figs. S2 and S3). C3 symmetry was applied to the closed conformation particle pool, yielding a 2.85-Å map (Fig. 1A and figs. S2 and S3).

The structure of S displays the characteristic overall shape observed for coronavirus S proteins in the closed and open conformations, with the closed form (~70%) predominating in our dataset (Fig. 1A and figs. S2 to S4). Model building of the closed form revealed additional density in the RBDs in our structure (Fig. 1B). The tubelike shape of this density was consistent with a fatty acid, with size and shape similar to that of linoleic acid (LA) bound to other proteins (Fig. 1B and fig. S5). Liquid chromatography–coupled electrospray ionization time-of-flight mass spectrometry (LC-MS) analysis confirmed the presence of a compound with the molecular weight of LA in our purified sample (Fig. 1C).

The hallmarks of free fatty acid (FFA) binding pockets in proteins are an extended “greasy” tube lined by hydrophobic amino acids, which accommodates the hydrocarbon tail, and a hydrophilic, often positively charged anchor for the acidic headgroup of the FFA. In our structure, a hydrophobic pocket mostly shaped by phenylalanines forms a bent tube into which the LA fits well (Fig. 1, D and E). The anchor for the headgroup carboxyl is provided by an arginine (Arg408) and a glutamine (Gln409) from the adjacent RBD in the trimer, giving rise to a composite LA binding site (Fig. 1E). We confirmed the presence of LA in all three binding pockets in the S trimer in the unsymmetrized (C1) closed structure (fig. S6). Similarly, masked 3D classification focusing on the RBDs could not identify any unoccupied pockets (fig. S7).

Our S construct contains alterations relative to native SARS-CoV-2 S—namely, addition of a trimerization domain and deletion of the polybasic cleavage site, neither of which alters the S conformation appreciably (fig. S8). Glycosylation sites are located away from the LA binding pocket and are largely native in our structure (table S2). Thus, neither glycosylation nor mutations are likely to affect the LA binding pocket. We compared S and RBD produced in insect cells with mammalian-produced S to identify any potential influence of differences in glycosylation on ACE2 binding by competition enzyme-linked immunosorbent assay (ELISA) (Fig. 2A). All three reagents bound ACE2 efficiently. We then used size exclusion chromatography (SEC) with purified proteins to further confirm ACE2 binding by S (Fig. 2B). The LA binding pocket and the receptor binding motif (RBM) are distal and nonoverlapping (Fig. 2C). Notably, in the LA-bound S, the RBM is ordered and buried at the interface between RBDs, whereas it was disordered in previously described SARS-CoV-2 S cryo-EM structures.

SARS-CoV-2 S can also adopt an open conformation (fig. S4), which is compatible with binding ACE2. In previous apo S cryo-EM structures, about 60 to 75% of the S trimers were in the open conformation, in contrast to our observation of ~70% in the closed conformation. This result could be due to LA stabilizing the closed conformation; if so, LA would be expected to reduce ACE2 binding. We performed surface plasmon resonance (SPR) experiments with biotinylated ACE2 immobilized on a streptavidin-coated chip (Fig. 2D and fig. S9). We first determined the dissociation constant (KD) of the RBD-ACE2 interaction to validate our assay. Our value (26 nM; fig. S9C) is in good agreement with that of previous work [44 nM], which used SPR with the RBD immobilized and ACE2 as an analyte. Apo S was prepared by applying Lipidex, the established method for removing lipids from lipid-binding proteins. A KD of 0.7 nM was obtained for the apo S-ACE2 interaction (fig. S9A). For the LA-bound S-ACE2 interaction, we obtained a KD of 1.4 nM (fig. S9B). We consistently obtained a markedly reduced resonance unit signal for LA-bound S compared with apo S at the same concentrations (Fig. 2D and fig. S9, A and B). This observation is consistent with the apo state having a higher percentage of S trimers in the open, ACE2-accessible conformation.

We characterized the affinity of the LA interaction both experimentally and computationally. Our SPR assays with immobilized RBD yielded a binding constant of ~41 nM, exhibiting a slow off-rate, consistent with tight binding of LA (fig. S10). Repeated molecular dynamics simulations of the entire locked LA-bound S trimer (three 100-ns simulations) using GROMACS-2019 corroborated the persistence of stable interactions between LA and the S trimer (movies S1 and S2). The affinity of LA binding to the S trimer will likely be higher than that of binding to the RBD alone, taking into account polar headgroup interactions with Arg408 and Gln409 of the adjacent RBD (Fig. 1E). The resolution of the RBDs in our open S cryo-EM structure was insufficient to either assign or rule out a ligand-bound pocket (fig. S3). However, the slow off-rate observed with the RBD monomer (fig. S10) suggests that LA binding could be maintained when the S trimer transiently converts into the open conformation. This is supported by our observation that LA was retained during S purification, in spite of S trimers adopting the open form ~30% of the time (fig. S2), and by our MD simulations with a modeled ligand-bound open S trimer (movie S3) in which all three LAs remained bound for 500 ns.

Next, we investigated the effect of LA in experiments with live SARS-CoV-2 infecting human epithelial cells. Remdesivir is an RNA-dependent RNA polymerase inhibitor and the first antiviral drug to show a benefit in the treatment of coronavirus disease 2019 (COVID-19) in clinical trials, albeit with considerable side effects at the doses required. LA supplementation at concentrations of 50 to 100 μM was previously shown to affect coronavirus entry and replication. We administered remdesivir at concentrations of 20, 64, and 200 nM, supplementing with 50 μM LA (Fig. 2E). Our results revealed synergy, with the dose of remdesivir required to suppress SARS-CoV-2 replication markedly reduced by the addition of LA (Fig. 2, E and F).

We superimposed our LA-bound structure on previous SARS-CoV-2 apo S structures in the closed conformation and identified a gating helix located directly at the entrance of the binding pocket (Fig. 3, A to C). This gating helix, which comprises Tyr365 and Tyr369, is displaced by ~6 Å when LA is bound, thus opening the pocket (Fig. 3, A and B). In the apo SARS-CoV-2 S trimer, a gap between adjacent RBDs places the hydrophilic anchor residues ~10 Å from the position of the LA headgroup (Fig. 3C). Upon LA binding, the adjacent RBD in the trimer moves toward its neighbor, and the anchor residues Arg408 and Gln409 lock down on the headgroup of LA (Fig. 3, C and D). Overall, this results in a compaction of trimer architecture in the region formed by the three RBDs, producing a locked S structure (Fig. 3D and movie S4).

We investigated whether the LA-binding pocket is conserved in the seven coronaviruses that infect humans (Fig. 4A and table S3). Sequence alignment shows that all residues lining the hydrophobic pocket and the anchor residues (Arg408 and Gln409) in SARS-CoV-2 are fully conserved in SARS-CoV (Fig. 4A). Structural alignment of LA-bound RBDs within the trimer of SARS-CoV-2 and apo SARS-CoV RBDs reveals that the LA binding pocket is present in SARS-CoV. The greasy tube is flanked by a gating helix as in SARS-CoV-2, with Arg395 and Gln396 of SARS-CoV positioned 10 and 11 Å from the entrance, respectively, in a conformation that is virtually identical to that of apo SARS-CoV-2 (Figs. 3C and 4B). In MERS-CoV, the gating helix and hydrophobic residues lining the pocket are also present. Tyr365, Tyr369, and Phe374 are substituted by likewise hydrophobic leucines and a valine, respectively (Fig. 4, A and C). The Arg408-Gln409 pair is not conserved; however, we identify Asn501, Lys502, and Gln466 as potential anchor residues, located on a β sheet and an α helix within the adjacent RBD, up to 11 Å from the entrance (Fig. 4C). Thus, the greasy tube and hydrophilic anchor appear to be present in MERS-CoV, suggesting convergent evolution. In HCoV OC43, the gating helix and hydrophobic residues that line the pocket are largely conserved, whereas Tyr365, Tyr369, and Phe374 are replaced by methionines and alanine, respectively (Fig. 4A). Arg413 is located on the same helix as Arg408 and Gln409 in SARS-CoV-2 and could serve as a hydrophilic anchor (Fig. 4D). No gap exists in this presumed apo form structure between the RBDs, which appear already in the locked conformation (Fig. 4D and fig. S11). In HCoV HKU1, the hydrophobic residues are again largely conserved, but a charged residue (Glu375) is positioned directly in front of the entrance, obstructing access for a putative ligand (Fig. 4E). The RBDs of HCoVs 229E and NL63 adopt a very different fold (fig. S13), and many of the LA binding residues are not present (Fig. 4A), thus hampering predictions of a binding site for fatty acids.

In summary, we find four molecular features that mediate LA binding to SARS-CoV-2 and potentially also to SARS-CoV and MERS-CoV S proteins: a conserved hydrophobic pocket, a gating helix, amino acid residues prepositioned to interact with the LA carboxyl headgroup, and loosely packed RBDs in the apo form. By contrast, in each of the four common circulating HCoVs, it appears that one or more of these four architectural prerequisites is lacking in the S protein structures (Fig. 4 and figs. S11 and S12). LA binding to SARS-CoV-2 S triggers a locking down of the hydrophilic anchor and a compaction of the RBD trimer (Fig. 3, C and D). In addition to stabilizing the closed conformation, this lockdown could also help stabilize the S1 region, which includes the N-terminal domain and the RBD. The RBM, central to ACE2 binding, appears to be conformationally preorganized in our structure (Fig. 2C), indicating a generally more rigid RBD trimer when LA is bound. Although direct cross-talk between the LA binding pocket and the RBM is not apparent from our structure (Fig. 2C), the conformational changes in the RBD trimer (Fig. 3) could affect ACE2 docking and infectivity, as indicated by our SPR assays that show reduced levels of S binding in the presence of LA (Fig. 2D). The S protein’s tight binding of LA originates from a well-defined size and shape complementarity afforded by the pocket (Fig. 1, B and D). The LA binding pocket thus presents a promising target for future development of small-molecule inhibitors that, for example, could irreversibly lock S in the closed conformation and interfere with receptor interactions. It is noteworthy in this context that a fatty acid binding pocket was exploited previously to develop potent small-molecule antiviral drugs to treat rhinovirus, locking viral surface proteins in a conformation incompatible with receptor binding. These antivirals were successful in human clinical trials.

A recent proteomic and metabolomic study of COVID-19 patient sera showed continuous decrease of FFAs, including LA. Lipid metabolome remodeling is a common element of viral infection. For coronaviruses, the LA–to–arachidonic acid metabolic pathway was identified as central to lipid remodeling. We hypothesize that LA sequestration by SARS-CoV-2 could confer a tissue-independent mechanism by which pathogenic coronavirus infection may drive immune dysregulation and inflammation. Our findings provide a direct structural link between LA, COVID-19 pathology, and the virus itself and suggest that both the LA binding pocket within the S protein and the multinodal LA signaling axis represent excellent therapeutic intervention points to treat SARS-CoV-2 infections.

References 63

  1. 1.
  2. 2.

    A. Zumla, J. F. Chan, E. I. Azhar, D. S. Hui, K. Y. Yuen, Coronaviruses - drug discovery and therapeutic options. Nat. Rev. Drug Discov. 15, 327–347 (2016 ).

    Not in our library10.1038/nrd.2015.37

  3. 3.

    Z. Varga, A. J. Flammer, P. Steiger, M. Haberecker, R. Andermatt, A. S. Zinkernagel, M. R. Mehra, R. A. Schuepbach, F. Ruschitzka, H. Moch, Endothelial cell infection and endotheliitis in COVID-19. Lancet 395, 1417–1418 (2020 ).

    Not in our library10.1016/s0140-6736(20)30937-5

  4. 4.

    V. G. Puelles, M. Lütgehetmann, M. T. Lindenmeyer, J. P. Sperhake, M. N. Wong, L. Allweiss, S. Chilla, A. Heinemann, N. Wanner, S. Liu, F. Braun, S. Lu, S. Pfefferle, A. S. Schröder, C. Edler, O. Gross, M. Glatzel, D. Wichmann, T. Wiech, S. Kluge, K. Pueschel, M. Aepfelbacher, T. B. Huber, Multiorgan and Renal Tropism of SARS-CoV-2. N. Engl. J. Med. 383, 590–592 (2020 ).

    Not in our library10.1056/nejmc2011400

  5. 5.

    M. Hoffmann, H. Kleine-Weber, S. Schroeder, N. Krüger, T. Herrler, S. Erichsen, T. S. Schiergens, G. Herrler, N.-H. Wu, A. Nitsche, M. A. Müller, C. Drosten, S. Pöhlmann, SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 181, 271–280.e8 (2020 ).

    Not in our library10.1016/j.cell.2020.02.052

  6. 6.

    M. Letko, A. Marzi, V. Munster, Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat. Microbiol. 5, 562–569 (2020 ).

    Not in our library10.1038/s41564-020-0688-y

  7. 7.

    A. C. Walls, Y.-J. Park, M. A. Tortorici, A. Wall, A. T. McGuire, D. Veesler, Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell 181, 281–292.e6 (2020 ).

    Not in our library10.1016/j.cell.2020.02.058

  8. 8.

    M. Hoffmann, H. Kleine-Weber, S. Pöhlmann, A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells. Mol. Cell 78, 779–784.e5 (2020 ).

    Not in our library10.1016/j.molcel.2020.04.022

  9. 9.
  10. 10.
  11. 11.

    C. Qin, L. Zhou, Z. Hu, S. Zhang, S. Yang, Y. Tao, C. Xie, K. Ma, K. Shang, W. Wang, D.-S. Tian, Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin. Infect. Dis. 71, 762–768 (2020 ).

    Not in our library10.1093/cid/ciaa248

  12. 12.

    M. Z. Tay, C. M. Poh, L. Rénia, P. A. MacAry, L. F. P. Ng, The trinity of COVID-19: Immunity, inflammation and intervention. Nat. Rev. Immunol. 20, 363–374 (2020 ).

    Not in our library10.1038/s41577-020-0311-8

  13. 13.
  14. 14.

    F. Amanat, D. Stadlbauer, S. Strohmeier, T. H. O. Nguyen, V. Chromikova, M. McMahon, K. Jiang, G. A. Arunkumar, D. Jurczyszak, J. Polanco, M. Bermudez-Gonzalez, G. Kleiner, T. Aydillo, L. Miorin, D. S. Fierer, L. A. Lugo, E. M. Kojic, J. Stoever, S. T. H. Liu, C. Cunningham-Rundles, P. L. Felgner, T. Moran, A. García-Sastre, D. Caplivski, A. C. Cheng, K. Kedzierska, O. Vapalahti, J. M. Hepojoki, V. Simon, F. Krammer, A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat. Med. 26, 1033–1036 (2020 ).

    Not in our library10.1038/s41591-020-0913-5

  15. 15.

    D. J. Fitzgerald, P. Berger, C. Schaffitzel, K. Yamada, T. J. Richmond, I. Berger, Protein complex expression by using multigene baculoviral vectors. Nat. Methods 3, 1021–1032 (2006 ).

    Not in our library10.1038/nmeth983

  16. 16.

    16 To produce S glycoprotein, we used baculovirus-infected insect cells (Hi5) cultured in ESF 921 media from Expression Systems, which contains cod liver oil as a nutrient supplement. Cod liver oil contains hundreds of FFAs, including LA (38), a possible source of the fatty acid. In parallel to our work, other researchers determined cryo-EM structures of S expressed in a mammalian system (HEK293) in serum and protein-free media (39, 40). The tube-shaped density we identified in our study is also present in those structures (but was not assigned or interpreted). Thus, we conclude that LA binding in the SARS-CoV-2 S pocket is not dependent on the expression system or media used.

    Not in our library

  17. 17.

    D. Wrapp, N. Wang, K. S. Corbett, J. A. Goldsmith, C.-L. Hsieh, O. Abiona, B. S. Graham, J. S. McLellan, Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260–1263 (2020 ).

    Not in our library10.1126/science.abb2507

  18. 18.

    M. A. Tortorici, A. C. Walls, Y. Lang, C. Wang, Z. Li, D. Koerhuis, G.-J. Boons, B.-J. Bosch, F. A. Rey, R. J. de Groot, D. Veesler, Structural basis for human coronavirus attachment to sialic acid receptors. Nat. Struct. Mol. Biol. 26, 481–489 (2019 ).

    Not in our library10.1038/s41594-019-0233-y

  19. 19.
  20. 20.

    J. M. Gullett, M. G. Cuypers, M. W. Frank, S. W. White, C. O. Rock, A fatty acid-binding protein of Streptococcus pneumoniae facilitates the acquisition of host polyunsaturated fatty acids. J. Biol. Chem. 294, 16416–16428 (2019 ).

    Not in our library10.1074/jbc.ra119.010659

  21. 21.

    J. Wang, E. J. Murphy, J. C. Nix, D. N. M. Jones, Aedes aegypti Odorant Binding Protein 22 selectively binds fatty acids through a conformational change in its C-terminal tail. Sci. Rep. 10, 3300 (2020 ).

    Not in our library10.1038/s41598-020-60242-9

  22. 22.

    J. Shang, G. Ye, K. Shi, Y. Wan, C. Luo, H. Aihara, Q. Geng, A. Auerbach, F. Li, Structural basis of receptor recognition by SARS-CoV-2. Nature 581, 221–224 (2020 ).

    Not in our library10.1038/s41586-020-2179-y

  23. 23.

    J. F. Glatz, J. H. Veerkamp, Removal of fatty acids from serum albumin by Lipidex 1000 chromatography. J. Biochem. Biophys. Methods 8, 57–61 (1983 ).

    Not in our library10.1016/0165-022x(83)90021-0

  24. 24.

    H. J. C. Berendsen, D. van der Spoel, R. van Drunen, GROMACS: A message-passing parallel molecular dynamics implementation. Comput. Phys. Commun. 91, 43–56 (1995 ).

    Not in our library10.1016/0010-4655(95)00042-e

  25. 25.

    J. H. Beigel, K. M. Tomashek, L. E. Dodd, A. K. Mehta, B. S. Zingman, A. C. Kalil, E. Hohmann, H. Y. Chu, A. Luetkemeyer, S. Kline, D. Lopez de Castilla, R. W. Finberg, K. Dierberg, V. Tapson, L. Hsieh, T. F. Patterson, R. Paredes, D. A. Sweeney, W. R. Short, G. Touloumi, D. C. Lye, N. Ohmagari, M. Oh, G. M. Ruiz-Palacios, T. Benfield, G. Fätkenheuer, M. G. Kortepeter, R. L. Atmar, C. B. Creech, J. Lundgren, A. G. Babiker, S. Pett, J. D. Neaton, T. H. Burgess, T. Bonnett, M. Green, M. Makowski, A. Osinusi, S. Nayak, H. C. Lane, Remdesivir for the Treatment of Covid-19 - Preliminary Report. N. Engl. J. Med. 10.1056/NEJMoa2007764 (2020 ).

    Not in our library10.1056/nejmoa2007764

  26. 26.
  27. 27.
  28. 28.

    A. C. Walls, M. A. Tortorici, B. Frenz, J. Snijder, W. Li, F. A. Rey, F. DiMaio, B.-J. Bosch, D. Veesler, Glycan shield and epitope masking of a coronavirus spike protein observed by cryo-electron microscopy. Nat. Struct. Mol. Biol. 23, 899–905 (2016 ).

    Not in our library10.1038/nsmb.3293

  29. 29.

    J. Badger., Structural analysis of a series of antiviral agents complexed with human rhinovirus 14. Proc. Natl. Acad. Sci. U.S.A. 85, 3304–3308 (1988 ).

    Not in our library10.1073/pnas.85.10.3304

  30. 30.

    M. A. Oliveira, R. Zhao, W.-M. Lee, M. J. Kremer, I. Minor, R. R. Rueckert, G. D. Diana, D. C. Pevear, F. J. Dutko, M. A. McKinlay, M. G. Rossmann, The structure of human rhinovirus 16. Structure 1, 51–68 (1993 ).

    Not in our library10.1016/0969-2126(93)90008-5

  31. 31.

    V. Casanova, F. H. Sousa, C. Stevens, P. G. Barlow, Antiviral therapeutic approaches for human rhinovirus infections. Future Virol. 13, 505–518 (2018 ).

    Not in our library10.2217/fvl-2018-0016

  32. 32.

    K. K. W. To, C. C. Y. Yip, K. Y. Yuen, Rhinovirus - From bench to bedside. J. Formos. Med. Assoc. 116, 496–504 (2017 ).

    Not in our library10.1016/j.jfma.2017.04.009

  33. 33.

    B. Shen, X. Yi, Y. Sun, X. Bi, J. Du, C. Zhang, S. Quan, F. Zhang, R. Sun, L. Qian, W. Ge, W. Liu, S. Liang, H. Chen, Y. Zhang, J. Li, J. Xu, Z. He, B. Chen, J. Wang, H. Yan, Y. Zheng, D. Wang, J. Zhu, Z. Kong, Z. Kang, X. Liang, X. Ding, G. Ruan, N. Xiang, X. Cai, H. Gao, L. Li, S. Li, Q. Xiao, T. Lu, Y. Zhu, H. Liu, H. Chen, T. Guo, Proteomic and Metabolomic Characterization of COVID-19 Patient Sera. Cell 182, 59–72.e15 (2020 ).

    Not in our library10.1016/j.cell.2020.05.032

  34. 34.

    C. M. Goodwin, S. Xu, J. Munger, Stealing the Keys to the Kitchen: Viral Manipulation of the Host Cell Metabolic Network. Trends Microbiol. 23, 789–798 (2015 ).

    Not in our library10.1016/j.tim.2015.08.007

  35. 35.

    J. W. Schoggins, G. Randall, Lipids in innate antiviral defense. Cell Host Microbe 14, 379–385 (2013 ).

    Not in our library10.1016/j.chom.2013.09.010

  36. 36.

    M. M. Zaman, C. R. Martin, C. Andersson, A. Q. Bhutta, J. E. Cluette-Brown, M. Laposata, S. D. Freedman, Linoleic acid supplementation results in increased arachidonic acid and eicosanoid production in CF airway cells and in cftr-/- transgenic mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 299, L599–L606 (2010 ).

    Not in our library10.1152/ajplung.00346.2009

  37. 37.

    I. Kimura, A. Ichimura, R. Ohue-Kitano, M. Igarashi, Free Fatty Acid Receptors in Health and Disease. Physiol. Rev. 100, 171–210 (2020 ).

    Not in our library10.1152/physrev.00041.2018

  38. 38.

    S. Hauff, W. Vetter, Quantitation of cis- and trans-monounsaturated fatty acids in dairy products and cod liver oil by mass spectrometry in the selected ion monitoring mode. J. Agric. Food Chem. 57, 3423–3430 (2009 ).

    Not in our library10.1021/jf803665u

  39. 39.
  40. 40.

    A. G. Wrobel, D. J. Benton, P. Xu, C. Roustan, S. R. Martin, P. B. Rosenthal, J. J. Skehel, S. J. Gamblin, SARS-CoV-2 and bat RaTG13 spike glycoprotein structures inform on virus evolution and furin-cleavage effects. Nat. Struct. Mol. Biol. 27, 763–767 (2020 ).

    Not in our library10.1038/s41594-020-0468-7

All 63 references

Cited by papers we hold 13

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.